Technology matters: The clinical utility of HPV mRNA testing compared to DNA testing
Developments in cervical cancer screening have dramatically decreased disease incidence and mortality over the past few decades - but have also added confusion concerning the roles and clinical applications of new technologies that detect human papillomavirus (HPV). How should clinicians approach these new testing methods so that they can provide better quality of life and treatment planning for their patients?
In this online supplement, E. Marshall Austin, MD, PhD offers insights on the many questions clinicians may have about HPV testing modalities, including:
- What is the role of HPV in cervical cancer?
- How do performance data compare for HPV DNA and mRNA tests?
- What are the benefits of HPV mRNA testing?
Read this online supplement to learn more about the latest in developments in cervical cancer screening.
Download Supplement
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
